查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1737205

全球頭頸癌藥物市場：市場規模（按藥物、治療類型、給藥途徑、最終用戶和地區分類）、未來預測

Global Head And Neck Cancer Drugs Therapeutics Market Size By Therapeutic, By Therapy Type, By Route Of Administration, By End-User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

頭頸癌治療藥物市場規模及預測

2024 年頭頸癌藥物市場規模價值 19.3 億美元，預計到 2032 年將達到 33.9 億美元，2026 年至 2032 年的複合年成長率為 7.30%。

頭頸癌藥物包括一系列專門用於控制和治療頭頸部（包括口腔、咽喉、喉頭和鼻腔）癌症的藥物治療方法。

這包括一系列治療類別，包括化療、免疫療法、標靶治療和放射線治療。

這些藥物主要用於腫瘤學治療被診斷為頭頸癌的患者，這種疾病通常與吸菸、飲酒和人類乳突病毒 (HPV) 感染等風險因素有關。

頭頸癌通常與吸菸、飲酒和人類乳突病毒 (HPV) 感染等風險因素有關。

人們對頭頸癌認知的提高和精準醫療的進步正在推動對標靶治療的需求，使得該市場對於解決全球重大健康問題至關重要。

全球頭頸癌藥物市場動態

影響全球頭頸癌藥物市場的關鍵市場動態包括：

關鍵市場促進因素

頭頸癌發生率上升：根據美國國家癌症美國(NCI) 的數據，預計2024年美國將新增66,470例口腔癌、咽癌和喉癌病例，約佔新增癌症病例總數的3.4%。吸菸、飲酒和HPV感染等生活型態因素導致頭頸癌發生率上升，是治療藥物需求的主要促進因素。

治療方案的進步：藥物開發的不斷創新，尤其是標靶治療和免疫療法，正在提高治療效果並提高採用率。

提高意識和篩檢計畫：大眾對頭頸癌的認知不斷提高，並努力促進早期發現和定期篩檢，正在鼓勵更多患者尋求治療選擇。

增加研發投資：製藥公司投入大量資源進行新治療方法的研究和臨床試驗，推動市場成長。

醫療保健基礎設施的改善：醫療保健設施和腫瘤服務的擴展，特別是在發展中地區，促進了抗癌藥物的獲取，並促進了市場的擴大。

主要挑戰

治療費用高昂：晚期癌症治療的高昂費用會限制患者獲得治療的機會，並導致醫療服務可用性的差異。

副作用和毒性：某些抗癌藥物可能產生嚴重的副作用和長期毒性，導致患者無法堅持治療方法。

監管障礙：新療法的嚴格監管和冗長的核准流程可能會減緩市場進入速度，並阻礙患者及時獲得創新治療方法。

新興市場認知度低：許多新興國家缺乏認知度和醫療保健基礎設施不足可能會限制現有治療方法的採用。

來自替代療法的競爭：替代療法（包括自然療法和補充療法）的興起可能對傳統癌症治療構成挑戰。

主要趨勢

轉向個人化醫療：更重視基於個人基因圖譜和生物標記的個人化治療計劃，從而提高頭頸癌治療的有效性。

將科技融入護理：數位健康科技和遠端醫療的結合正在改善病患管理和治療方法的依從性。

合作與夥伴關係：製藥公司、研發機構和醫療保健提供者之間加強合作將加速藥物開發並促進創新。

注重聯合治療：採用多種治療方式的聯合治療趨勢由於患者治療效果的改善和抵抗力的降低而越來越受歡迎。

生物標記檢測的使用日益增多：生物標記檢測在患者分層中的使用日益增多，對於確定頭頸癌最有效的治療方法至關重要。

目錄

第1章全球頭頸癌藥物市場簡介

  • 市場概覽
  • 分析範圍
  • 先決條件

第2章執行摘要

第3章 已驗證的市場研究分析方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球頭頸癌藥物市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章全球頭頸癌藥物市場（按治療藥物）

  • 概述
  • PD抑制劑
  • 微管抑制劑
  • EGFR抑制劑

6. 全球頭頸癌藥物市場（依治療類型）

  • 概述
  • 外科治療
  • 放射線治療
  • 標靶治療
  • 免疫療法
  • 化療

7. 全球頭頸癌藥物市場（依給藥途徑）

  • 概述
  • 注射
  • 口服

8. 全球頭頸癌藥物市場（依最終用戶）

  • 概述
  • 零售和專業藥房
  • 醫院藥房
  • 網路藥局

9. 全球頭頸癌藥物市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他地區 (ROW)
    • 拉丁美洲
    • 中東和非洲

第10章全球頭頸癌藥物市場的競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第11章 公司簡介

  • Bristol-Myers Squibb
  • Merck & Co
  • Eli Lilly
  • Sanofi
  • Merck Group
  • AstraZeneca
  • Pfizer
  • Kura Oncology
  • Lion Biotechnologies

第12章 附錄

    • 相關分析
簡介目錄
Product Code: 58786

Head And Neck Cancer Drugs Therapeutics Market Size And Forecast

Head And Neck Cancer Drugs Therapeutics Market size was valued at USD 1.93 Billion in 2024 and is projected to reach USD 3.39 Billion by 2032, growing at a CAGR of 7.30% from 2026 to 2032.

The head and neck cancer drugs therapeutics encompasses a range of pharmaceutical treatments specifically designed for the management and treatment of cancers that occur in the head and neck region, including the oral cavity, pharynx, larynx, and nasal passages.

This includes various therapeutic categories, such as chemotherapy, immunotherapy, targeted therapy, and radiation therapy.

These drugs are used primarily in oncology to treat patients diagnosed with head and neck cancers, which are often associated with risk factors such as tobacco use, alcohol consumption, and human papillomavirus (HPV) infection.

The increasing prevalence of these cancers globally underscores the importance of this market, as effective treatment options are crucial for improving patient outcomes.

The rising awareness of head and neck cancers and advancements in precision medicine are propelling the demand for targeted therapies, making this market vital in addressing a significant health concern worldwide.

Global Head and Neck Cancer Drugs Therapeutics Market Dynamics

The key market dynamics that are shaping the global head and neck cancer drugs therapeutics market include:

Key Market Drivers

Rising Incidence of Head and Neck Cancers: According to the National Cancer Institute (NCI), an estimated 66,470 new cases of oral cavity, pharyngeal, and laryngeal cancers were diagnosed in the United States in 2024, representing approximately 3.4% of all new cancer cases. The increasing prevalence of head and neck cancers due to lifestyle factors such as smoking, alcohol consumption, and HPV infections is significantly driving demand for therapeutics.

Advancements in Treatment Options: Continuous innovations in drug development, particularly in targeted therapies and immunotherapies, are improving treatment efficacy, leading to higher adoption rates.

Growing Awareness and Screening Programs: Increased public awareness of head and neck cancers and initiatives promoting early detection and regular screenings are encouraging more patients to seek therapeutic options.

Increasing Research and Development Investments: Pharmaceutical companies are allocating significant resources to research and clinical trials for novel treatment modalities, stimulating market growth.

Improved Healthcare Infrastructure: The enhancement of healthcare facilities and oncology services, especially in developing regions, is facilitating access to cancer therapeutics and contributing to market expansion.

Key Challenges

High Treatment Costs: The elevated costs associated with advanced cancer therapies can limit patient access and result in disparities in treatment availability.

Side Effects and Toxicity: The potential for severe side effects and long-term toxicity associated with certain cancer drugs hinder patient adherence to treatment regimens.

Regulatory Hurdles: Stringent regulations and lengthy approval processes for new therapeutics can delay market entry and impede timely patient access to innovative treatments.

Limited Awareness in Emerging Markets: In many developing countries, insufficient awareness and inadequate healthcare infrastructure can restrict the adoption of available therapeutics.

Competition from Alternative Therapies: The rise of alternative treatment options, including natural and complementary therapies, can pose challenges for conventional cancer therapeutics.

Key Trends

Shift Towards Personalized Medicine: A growing emphasis on personalized treatment plans based on individual genetic profiles and biomarkers is enhancing the efficacy of head and neck cancer therapies.

Integration of Technology in Treatment: The incorporation of digital health technologies and telemedicine is improving patient management and adherence to treatment regimens.

Collaboration and Partnerships: Increased collaboration between pharmaceutical companies, research institutions, and healthcare providers is accelerating drug development and fostering innovation.

Focus on Combination Therapies: The trend of using combination therapies, which leverage multiple treatment modalities, is gaining popularity due to improved patient outcomes and reduced resistance.

Rising Use of Biomarker Testing: The growing utilization of biomarker testing for patient stratification is becoming essential for determining the most effective treatment approaches in head and neck cancer.

Global Head and Neck Cancer Drugs Therapeutics Market Regional Analysis

Here is a more detailed regional analysis of the global head and neck cancer drugs therapeutics market:

North America

North America is substantially dominating the Global Head and Neck Cancer Drugs Therapeutics Market and is expected to continue its dominance throughout the forecast period.

According to the American Cancer Society, an estimated 54,540 new cases of head and neck cancers are expected in the U.S. annually, highlighting the urgent need for effective treatment solutions.

The American Society of Clinical Oncology reports that since the FDA approval of pembrolizumab in 2016, the overall survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma has improved by 37%, compared to standard chemotherapy.

The North American market benefits from a well-established healthcare infrastructure, advanced research facilities, and significant investments in research and development by leading pharmaceutical companies.

This region is home to numerous biotech and pharmaceutical firms actively engaged in developing innovative therapies, including targeted treatments and immunotherapies specifically designed for head and neck cancers.

The presence of extensive clinical trial networks and regulatory agencies, such as the FDA, facilitates the timely approval and commercialization of new drugs.

The growing awareness of head and neck cancers and the availability of comprehensive treatment options contribute to an increasing patient population seeking therapies.

The North American market also faces challenges, including high treatment costs and the potential for disparities in access to care.

Despite these hurdles, the ongoing advancements in treatment modalities and the focus on personalized medicine position the North American head and neck cancer therapeutics market for sustained growth in the coming years.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region in the Global Head and Neck Cancer Drugs Therapeutics Market during the forecast period.

The increasing prevalence of head and neck cancers in countries like India, China, and Japan significantly contributes to the growing demand for effective treatment options.

In particular, the rise in tobacco and alcohol consumption, coupled with poor oral hygiene practices, has heightened the incidence of these cancers in the region.

The Asia-Pacific market is characterized by a rapidly evolving healthcare infrastructure, with substantial investments in healthcare facilities and services.

Governments in various countries are actively promoting cancer awareness campaigns and improving access to treatment, which is expected to lead to early diagnosis and better therapeutic outcomes.

The region also witnesses a surge in clinical trials focusing on innovative therapies, including targeted therapies and immunotherapies, tailored to the genetic and environmental factors prevalent in the population.

Partnerships between local pharmaceutical companies and global biotech firms are fostering research and development, accelerating the introduction of novel therapeutics into the market.

Global Head And Neck Cancer Drugs Therapeutics Market: Segmentation Analysis

The Global Head And Neck Cancer Drugs Therapeutics Market is Segmented on the basis of Therapeutic, Therapy Type, Route of Administration, End-User, and Geography.

Head And Neck Cancer Drugs Therapeutics Market, By Therapeutic

  • PD Inhibitors
  • Microtubule Inhibitors
  • EGFR Inhibitors

Based on the Therapeutic Category, the Global Head and Neck Cancer Drugs Therapeutics Market is categorized into PD Inhibitors, Microtubule Inhibitors, and EGFR Inhibitors. The PD Inhibitors segment is experiencing significant growth owing to their role in enhancing the immune response against cancer cells by blocking programmed cell death pathways. This has led to improved survival rates for patients with head and neck cancers.

Head And Neck Cancer Drugs Therapeutics Market, By Therapy Type

  • Surgery
  • Radiation Therapy
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

Based on the Therapy Type, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, and Chemotherapy. The Surgery segment dominates the market as surgery remains a primary treatment option, often employed to remove tumors and surrounding tissues, playing a crucial role in early-stage head and neck cancers.

Head And Neck Cancer Drugs Therapeutics Market, By Route of Administration

  • Injectable
  • Oral

Based on the Route of Administration, the Global Head and Neck Cancer Drugs Therapeutics Market is categorized into Injectable and Oral. Injectable segment dominates in the market. Injectable treatments are widely utilized in this market due to their rapid onset of action and ability to deliver higher concentrations of drugs directly into the bloodstream or tumors, ensuring effective management of cancer symptoms and treatment outcomes. This method is particularly important for medications that require close monitoring and precise dosing, such as chemotherapy and targeted therapies.

Head And Neck Cancer Drugs Therapeutics Market, By End User

  • Retail & Specialty Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Based on the End User, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment significantly dominates in this market, as they provide essential medications directly to patients undergoing treatment in healthcare facilities. These pharmacies are often equipped to handle complex drug regimens, ensuring timely access to necessary therapies for managing head and neck cancer.

Head And Neck Cancer Drugs Therapeutics Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the Global Head and Neck Cancer Drugs Therapeutics Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is substantially dominating the Global Head and Neck Cancer Drugs Therapeutics Market and is expected to continue its dominance throughout the forecast period. According to the American Cancer Society, an estimated 54,540 new cases of head and neck cancers are expected in the U.S. annually, highlighting the urgent need for effective treatment solutions. The American Society of Clinical Oncology reports that since the FDA approval of pembrolizumab in 2016, the overall survival rate for patients with recurrent or metastatic head and neck squamous cell carcinoma has improved by 37%, compared to standard chemotherapy.

Key Players

The "Global Head and Neck Cancer Drugs Therapeutics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Bristol-Myers Squibb, Merck & Co., Eli Lilly, Sanofi, Merck Group, AstraZeneca, Pfizer, Kura Oncology, and Lion Biotechnologies.

  • This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Head And Neck Cancer Drugs Therapeutics Market Key Developments

  • In April 2024, the OICR announced the launch of two new clinical trials as part of its Window-of-Opportunity (WOO) Network, which brought together Ontario researchers, doctors, and patients to investigate the biology of newly diagnosed and recurring malignancies.
  • In March 2024, 3T Biosciences ("3T"), an immunotherapy company that aimed to change the future of treatment for solid tumors and other immune-mediated diseases, announced that it had formed multiple new collaborations with leading academic centers and principal investigators to fuel 3T's best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) pHLA target discovery platform.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY THERAPEUTIC

  • 5.1 Overview
  • 5.2 PD Inhibitors
  • 5.3 Microtubule Inhibitors
  • 5.4 EGFR Inhibitors

6 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY THERAPY TYPE

  • 6.1 Overview
  • 6.2 Surgery
  • 6.3 Radiation Therapy
  • 6.4 Targeted Therapy
  • 6.5 Immunotherapy
  • 6.6 Chemotherapy

7 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1 Overview
  • 7.2 Injectable
  • 7.3 Oral

8 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY END-USER

  • 8.1 Overview
  • 8.2 Retail & Specialty Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies

9 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Rest of the World
    • 9.5.1 Latin America
    • 9.5.2 Middle East and Africa

10 GLOBAL HEAD AND NECK CANCER DRUGS THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Development Strategies

11 COMPANY PROFILES

  • 11.1 Bristol-Myers Squibb
    • 11.1.1 Overview
    • 11.1.2 Financial Performance
    • 11.1.3 Product Outlook
    • 11.1.4 Key Developments
  • 11.2 Merck & Co
    • 11.2.1 Overview
    • 11.2.2 Financial Performance
    • 11.2.3 Product Outlook
    • 11.2.4 Key Developments
  • 11.3 Eli Lilly
    • 11.3.1 Overview
    • 11.3.2 Financial Performance
    • 11.3.3 Product Outlook
    • 11.3.4 Key Developments
  • 11.4 Sanofi
    • 11.4.1 Overview
    • 11.4.2 Financial Performance
    • 11.4.3 Product Outlook
    • 11.4.4 Key Developments
  • 11.5 Merck Group
    • 11.5.1 Overview
    • 11.5.2 Financial Performance
    • 11.5.3 Product Outlook
    • 11.5.4 Key Developments
  • 11.6 AstraZeneca
    • 11.6.1 Overview
    • 11.6.2 Financial Performance
    • 11.6.3 Product Outlook
    • 11.6.4 Key Developments
  • 11.7 Pfizer
    • 11.7.1 Overview
    • 11.7.2 Financial Performance
    • 11.7.3 Product Outlook
    • 11.7.4 Key Developments
  • 11.8 Kura Oncology
    • 11.8.1 Overview
    • 11.8.2 Financial Performance
    • 11.8.3 Product Outlook
    • 11.8.4 Key Developments
  • 11.9 Lion Biotechnologies
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Developments

12 Appendix

    • 12.1.1 Related Research